Xitra Therapeutics GmbH is a biotechnology company dedicated to the discovery and development of innovative small molecules targeting the Mas and MrgD receptors within the Alternative Renin-Angiotensin System. These molecules mimic the naturally occurring peptide angiotensin-(1-7) but offer enhanced drug properties, including increased potency and oral bioavailability.
As a subsidiary of Constant Therapeutics, Xitra Therapeutics leverages cutting-edge research to develop therapies aimed at treating common and rare diseases. Our mission is to advance scientific knowledge and translate it into effective treatments that improve patient outcomes.
Company Details
Xitra Therapeutics Gmbh Questions
Xitra Therapeutics Gmbh's website is https://www.xitratherapeutics.com/
Xitra Therapeutics Gmbh's LinkedIn profile is https://de.linkedin.com/company/xitra-therapeutics
Xitra Therapeutics Gmbh has
4 employees.
View email and phone details for 4
employees at Xitra Therapeutics Gmbh.
Xitra Therapeutics Gmbh's industry is
Biotechnology Research
Xitra Therapeutics Gmbh's top competitors are
Sensid Gmbh,
Pro Return Gmbh,
Saxovent,
Dispothek Filmdisposition & Beratung Gmbh,
Mycala,
Markus Coenen - Wirkung Im Yes-Modus,
E-Wikom Gmbh,
Pagestreet,
Koko Beratungsgesellschaft,
German Animal Welfare Federation.
Xitra Therapeutics Gmbh's categories are Biotechnology Research
